Roche Holding AG (ROP.SW)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF bn | 58 | 63 | 66 | 60 | 62 | 62 | 61 | 63 |
| Operating profit | CHF bn | 19 | 19 | ||||||
| Net profit | CHF bn | 14 | 14 | 12 | 11 | 8 | 13 | 12 | 16 |
| EPS reported | CHF | 16.04 | 15.30 | ||||||
| Operating cashflow per share | CHF | 22.40 | 22.74 | ||||||
| Capex per share | CHF | 4.71 | 4.50 | ||||||
| FCF per share | CHF | 17.69 | 18.24 | ||||||
| Free cash flow | CHF bn | 14 | 15 | ||||||
| Net debt | CHF bn | 16 | 22 | ||||||
| Book value equity | CHF bn | 34 | 33 | ||||||
| Book value per share | CHF | 42.09 | 40.40 | ||||||
| Number of shares | m | 803 | 809.26 | ||||||
| DPS (TTM paid) | CHF | 9.80 | 9.80 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 20.46 | - | ||||||
| P/B LTM | x | 7.73 | 7.99 | ||||||
| P/S LTM | x | 4.25 | 4.29 | ||||||
| P/FCF LTM | x | 18.55 | 17.70 | ||||||
| EV/EBITDA LTM | x | 12.75 | 13.72 | ||||||
| EV/Sales LTM | x | 4.70 | 5.23 | ||||||
| Earnings Yield LTM | % | +4.89% | +4.15% | ||||||
| FCF Yield | % | +5.39% | +5.65% | ||||||
| Quality | |||||||||
| ROE | % | +38.10% | +37.12% | ||||||
| ROIC | % | +20.28% | +20.82% | ||||||
| Operating margin | % | +31.32% | +31.92% | ||||||
| Gross margin | % | +73.53% | +73.32% | ||||||
| FCF/Sales | % | +22.89% | +24.23% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +55.88% | +48.69% | ||||||
| Sales Growth YoY | % | -1.41% | -2.34% | ||||||
| Net Income Growth YoY | % | +55.61% | +49.10% | ||||||
| FCF Growth | % | -6.65% | -2.14% | ||||||
| Operating Profit Growth | % | +43.58% | +44.99% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +3.21% | +2.67% | ||||||
| Dividend Growth | % | +1.03% | +1.03% | ||||||
| Payout Ratio | % | +65.10% | +65.10% | ||||||
| FCF/Debt | x | 0.42 | 0.46 | ||||||
| Net Debt/EBITDA | x | 1.22 | 1.25 | ||||||
| EBIT/Net interest | x | 14.28 | 14.07 | ||||||
| Net debt/market cap | % | +12.11% | +10.88% | ||||||
| Net debt/Equity | x | 0.48 | 0.68 | ||||||
| Gross debt/equity | x | 0.98 | 0.97 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free